Is Trupanion, Inc. (TRUP) A Good Stock To Buy Now?

Is TRUP a good stock to buy? We came across a bullish thesis on Trupanion, Inc. on Consume Your Own Tech Investing’s Substack. In this article, we will summarize the bulls’ thesis on TRUP. Trupanion, Inc.'s share was trading at $27.91 as of April 21st. TRUP’s trailing and forward P/E were 62.02 and 1.43k respectively according to Yahoo Finance.

Trupanion (TRUP) is an under-the-radar pet insurance specialist whose shares appear mispriced relative to the durability of its subscription-driven model. The company operates a cost-plus structure where roughly 70% of subscription revenue is paid to veterinarians, while management targets long-term operating margins of about 15% and deploys capital only expected internal rates of return on new pet acquisitions fall within 30–40%. This disciplined framework positions Trupanion as a subscription compounder than a traditional insurer.

The sharp margin compression in 2022–2023 stemmed from pricing lag as veterinary costs accelerated faster than premium adjustments, temporarily reducing lifetime value and weighing on sentiment, rather than a breakdown of the model. Pricing has begun to catch up, supporting margin recovery and reinforcing underlying economics. While growth has normalized from the 30–40% pandemic-era expansion to mid-teens due to demand pull-forward, increased competition, and deliberate moderation in acquisition spend, the structural backdrop remains attractive low pet insurance penetration and veterinary costs.

Trupanion’s point-of-care distribution advantage through Trupanion Express, alongside strong retention, underpins its competitive moat. At $27 per share, the company enterprise value is under $1 billion, or less than 1x subscription revenue, a level that implies structural impairment despite management guiding to 13–15% subscription growth and ~15% margins in FY2026.

If achieved, Trupanion could compound intrinsic value over time, with upside driven by earnings durability rather than multiple expansion. The balance sheet remains solid and operational execution has improved after management refinements, including prior pricing corrections. Overall, Trupanion represents a disciplined, underappreciated compounder with improving economics, where normalized margins and mid-teens growth could drive long-term upside.

Previously, we covered a bullish thesis on Lemonade, Inc. (LMND) by Oliver | MMMT Wealth in April 2025, which highlighted tariff resistance, diversified insurance mix and resilience versus auto-focused peers. LMND's stock has appreciated by approximately 135.00% since our coverage. Consume Your Own Tech Investing’s Substack shares a similar view but emphasizes Trupanion's subscription economics, margin recovery and capital discipline.

Trupanion, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held TRUP at the end of the fourth quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of TRUP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TRUP and that has 10,000% upside potential, check out our report about this cheapest AI stock.